Invention Grant
- Patent Title: Substituted pyrimidine compounds as phosphatidylinositol 3-kinase delta inhibitor and use thereof
-
Application No.: US15551679Application Date: 2016-03-04
-
Publication No.: US10077258B2Publication Date: 2018-09-18
- Inventor: Yong Wang , Xiaorong Liu , Dandan Huang , Yan Zhang , Yumei Kai
- Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTD.
- Applicant Address: CN Nanjing
- Assignee: NANJING SANHOME PHARMACEUTICAL CO., LTD.
- Current Assignee: NANJING SANHOME PHARMACEUTICAL CO., LTD.
- Current Assignee Address: CN Nanjing
- Agency: Parker Highlander PLLC
- Priority: CN201510101229 20150306
- International Application: PCT/CN2016/075618 WO 20160304
- International Announcement: WO2016/141855 WO 20160915
- Main IPC: C07D405/12
- IPC: C07D405/12 ; C07D401/12

Abstract:
The present invention belongs to the field of medicinal chemistry, and relates to substituted pyrimidine compounds as phosphatidylinositol 3-kinase (PI3K) δ inhibitor and a use thereof. In particular, the present invention provides a compound as shown by formula I or an isomer, pharmaceutically acceptable salt, solvate or prodrug thereof, the preparation methods of same and pharmaceutical compositions containing these compounds and a use of these compounds or compositions for treating cancer, hyperblastosis diseases or inflammatory diseases. The compounds of the present invention have a good inhibiting activity on PI3Kδ and have a high selectivity. It is hoped that these will be therapeutic agents for cancer, hyperblastosis diseases or inflammatory diseases.
Public/Granted literature
- US20180037576A1 SUBSTITUTED PYRIMIDINE COMPOUNDS AS PHOSPHATIDYLINOSITOL 3-KINASE DELTA INHIBITOR AND USE THEREOF Public/Granted day:2018-02-08
Information query